S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
NASDAQ:LNTH

Lantheus (LNTH) Stock Price, News & Analysis

$66.27
+1.22 (+1.88%)
(As of 02/23/2024 ET)
Today's Range
$65.00
$66.60
50-Day Range
$51.07
$66.27
52-Week Range
$50.20
$100.85
Volume
1.22 million shs
Average Volume
1.29 million shs
Market Capitalization
$4.54 billion
P/E Ratio
46.34
Dividend Yield
N/A
Price Target
$108.14

Lantheus MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
63.2% Upside
$108.14 Price Target
Short Interest
Healthy
7.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.67
Upright™ Environmental Score
News Sentiment
0.62mentions of Lantheus in the last 14 days
Based on 28 Articles This Week
Insider Trading
Selling Shares
$37,960 Sold Last Quarter
Proj. Earnings Growth
-0.55%
From $5.44 to $5.41 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.92 out of 5 stars

Medical Sector

59th out of 941 stocks

Diagnostic Substances Industry

1st out of 13 stocks


LNTH stock logo

About Lantheus Stock (NASDAQ:LNTH)

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.

LNTH Stock Price History

LNTH Stock News Headlines

LNTH Apr 2024 110.000 call
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN?
Financial giants have been injecting millions into the crypto market. The big players are going all in on crypto… but what are they gearing up for? There is a significant event on the horizon that will shape the future of Bitcoin—the upcoming Bitcoin halving event…We're revealing all the secrets behind the financial elite's bold moves in crypto during our LIVE, online event.
Assessing Lantheus Holdings: Insights From 4 Financial Analysts
LNTH Mar 2024 30.000 put
Wall Street Pushing a 'Crypto Revolution' - Will You Miss Out… AGAIN?
Financial giants have been injecting millions into the crypto market. The big players are going all in on crypto… but what are they gearing up for? There is a significant event on the horizon that will shape the future of Bitcoin—the upcoming Bitcoin halving event…We're revealing all the secrets behind the financial elite's bold moves in crypto during our LIVE, online event.
Lantheus Holdings Gains On Announcement Of Upbeat Q4 Report
Lantheus Holdings, Inc. (LNTH)
Lantheus Q4 2023 Earnings Preview
Lantheus (LNTH) Set to Announce Quarterly Earnings on Thursday
LNTH Feb 2024 80.000 call
LNTH Jul 2024 100.000 call
LNTH Apr 2024 40.000 call
See More Headlines
Receive LNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
2/23/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:LNTH
Employees
698
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$108.14
High Stock Price Target
$127.00
Low Stock Price Target
$95.00
Potential Upside/Downside
+63.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$28.07 million
Pretax Margin
7.99%

Debt

Sales & Book Value

Annual Sales
$935.06 million
Cash Flow
$5.53 per share
Book Value
$6.50 per share

Miscellaneous

Free Float
67,462,000
Market Cap
$4.54 billion
Optionable
Optionable
Beta
0.53
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report














LNTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Lantheus stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lantheus in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LNTH shares.
View LNTH analyst ratings
or view top-rated stocks.

What is Lantheus' stock price target for 2024?

7 Wall Street research analysts have issued twelve-month target prices for Lantheus' shares. Their LNTH share price targets range from $95.00 to $127.00. On average, they expect the company's share price to reach $108.14 in the next twelve months. This suggests a possible upside of 63.2% from the stock's current price.
View analysts price targets for LNTH
or view top-rated stocks among Wall Street analysts.

How have LNTH shares performed in 2024?

Lantheus' stock was trading at $62.00 at the beginning of the year. Since then, LNTH shares have increased by 6.9% and is now trading at $66.27.
View the best growth stocks for 2024 here
.

Are investors shorting Lantheus?

Lantheus saw a drop in short interest during the month of January. As of January 31st, there was short interest totaling 4,890,000 shares, a drop of 11.4% from the January 15th total of 5,520,000 shares. Based on an average daily volume of 1,300,000 shares, the days-to-cover ratio is currently 3.8 days. Currently, 7.3% of the company's shares are sold short.
View Lantheus' Short Interest
.

When is Lantheus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our LNTH earnings forecast
.

How were Lantheus' earnings last quarter?

Lantheus Holdings, Inc. (NASDAQ:LNTH) posted its earnings results on Thursday, November, 4th. The medical equipment provider reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. The medical equipment provider had revenue of $102.10 million for the quarter, compared to the consensus estimate of $97.13 million. Lantheus had a net margin of 8.63% and a trailing twelve-month return on equity of 70.13%. The business's revenue for the quarter was up 15.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.04 EPS.

What guidance has Lantheus issued on next quarter's earnings?

Lantheus updated its first quarter 2024 earnings guidance on Thursday, February, 22nd. The company provided EPS guidance of 1.500-1.540 for the period, compared to the consensus estimate of 1.510. The company issued revenue guidance of $347.0 million-$355.0 million, compared to the consensus revenue estimate of $336.4 million.

What is Mary Anne Heino's approval rating as Lantheus' CEO?

4 employees have rated Lantheus Chief Executive Officer Mary Anne Heino on Glassdoor.com. Mary Anne Heino has an approval rating of 51% among the company's employees. This puts Mary Anne Heino in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lantheus own?
When did Lantheus IPO?

(LNTH) raised $75 million in an initial public offering on Thursday, June 25th 2015. The company issued 7,900,000 shares at $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager.

Who are Lantheus' major shareholders?

Lantheus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.18%), Price T Rowe Associates Inc. MD (2.39%), Price T Rowe Associates Inc. MD (2.39%), Westfield Capital Management Co. LP (2.28%), Reinhart Partners LLC. (1.98%) and Dimensional Fund Advisors LP (1.67%). Insiders that own company stock include Andrea Sabens, Brian A Markison, Carol Walker, Daniel Niedzwiecki, Etienne Montagut, Gerard Ber, Heinz Christoph Maeusli, John J Bolla, Mary Anne Heino, Michael P Duffy, Michael P Duffy, Minnie Baylor-Henry, Paul Blanchfield, Robert J Jr Marshall and Sam R Leno.
View institutional ownership trends
.

How do I buy shares of Lantheus?

Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LNTH) was last updated on 2/24/2024 by MarketBeat.com Staff